Matters Relating to Business Plans and Growth Potential
Filed with TSE · · 84 pages · English
Corporate As a global biotech venture, we pursue new possibilities in SLC transporter drug discovery to develop Philosophy innovative medicines that address global unmet medical needs and help people maintain health and hope President and CEO Masuhiro Yoshitake For diseases where current treatments have reached their limits, it is essential to explore new drugs with previously untapped mechanisms
Later from J-Pharma Co.,Ltd
- Notice Regarding Issuance of New Shares as Restricted Stock Compensation to Directors and Executive Officers
- Non-consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)
- J-Pharma Enters into Non-Binding Term Sheet with European Biotech Company for JPH034
- J-Pharma Selected for Funding under AMED's Global Research and Development Support Project for the Treatment of Intractable/Rare Diseases
- Notice of Grant approval and Commencement of the Grant-Funded Project under AMED’s GRiT Program
Follow J-Pharma Co.,Ltd into a list and get an email when it puts out news.
Follow J-Pharma Co.,Ltd